E. N. Gal-Yam, S. Jeong, A. Tanay, G. Egger, A. S. Lee and P. A. Jones, “Constitutive Nucleosome Depletion and Ordered Factor Assembly at the GRP78 Promoter Revealed by Single Molecule Footprinting,” PLoS Genetics, Vol. 2, No. 9, 2006, p. 160. doi:10.1371/journal.pgen.0020160
 R. Appanah, D. R. Dickerson, P. Goyal, M. Groudine and M. C. Lorincz, “An Unmethylated 3’Promoter-Proximal Region Is Required for Efficient Transcription Initiation,” PLoS Genetics, Vol. 3, No. 2, 2007, p. 27. doi:10.1371/journal.pgen.0030027
 K. Banno, M. Yanokura, N. Susumu, M. Kawaguchi, N. Hirao, A. Hirasawa, K. Tsukazaki and D. Aoki, “Relationship of Aberrant DNA Hypermethylation Of Cancer-Related Genes with Carcinogenesis of Endometrial Cancer,” Oncology Reports, Vol. 16, No. 6, 2006, pp. 1189-1196.
 M. Kawaguchi, K. Banno, M. Yanokura, Y. Kobayashi, A. Kishimi, S. Ogawa, I. Kisu, H. Nomura, A. Hirasawa, N. Susumu and D. Aoki, “Analysis of Candidate Target Genes for Mononucleotide Repeat Mutation in Microsatellite Instability-High (MSH-H) Endometrial Cancer,” International Journal of Oncology, Vol. 35, No. 5, 2009, pp. 977-982.
 T. Kanaya, S. Kyo, Y. Maida, N. Yatabe, M. Tanaka, M. Nakamura and M. Inoue, “Frequent Hypermethylation of MLH1 Promoter in Normal Endometrium of Patients with Endometrial Cancers,” Oncogene, Vol. 22, No. 15, 2003, pp. 2352-2360. doi:10.1038/sj.onc.1206365
 H. J. Yang, V. W. Liu, Y. Wang, P. C. Tsang and H. Y. Ngan, “Differential DNA Methylation Profiles in Gynecological Cancers and Correlation with Clinico-Pathological Data,” BMC Cancer, Vol. 6, 2006, p. 212. doi:10.1186/1471-2407-6-212
 J. Sakaguchi, S. Kyo, T. Kanaya, Y. Maida, M. Hashimoto, M. Nakamura, K. Yamada and M. Inoue, “Aberrant Expression and Mutations of TGF-Beta Receptor Type II Gene in Endometrial Cancer,” Gynecologic Oncology, Vol. 98, No. 3, 2005, pp. 427-433. doi:10.1016/j.ygyno.2005.04.031
 B. P. Whitcomb, D. G. Mutch, T. J. Herzog, J. S. Rader, R. K. Gibb and P. J. Goodfellow, “Frequent HOXA11 and THBS2 Promoter Methylation, and a Methylator Pheno-type in Endometrial Adenocarcinoma,” Clinical Cancer Research, Vol. 9, No. 6, 2003, pp. 2277-2287.
 M. Sasaki, M. Kaneuchi, N. Sakuragi and R. Dahiya, “Multiple Promoters of Catechol-O-Methyltransferase Gene Are Selectively Inactivated by CpG Hypermethylation in Endometrial Cancer,” Cancer Research, Vol. 63, No. 14, 2003, pp. 3101-3106.
 H. Fiegl, C. Gattringer, A. Widschwendter, A. Schneitter, A. Ramoni, D. Sarlay, I. Gaugg, G. Goebel, et al., “Methylated DNA Collected by Tampons: A New Tool to Detect Endometrial Cancer,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 13, No. 5, 2004, pp. 882-888.
 M. Toyota, Y. Sasaki, A. Satoh, et al., “Epigenetic Inactivation of CHFR in Human Tumors,” Proceedings of the National Academy of Sciences, Vol. 100, No. 13, 2003, pp. 7818-7823. doi:10.1073/pnas.1337066100
 J. S. Kim, J. W. Kim, J. Han, Y. M. Shim, J. Park and D. H. Kim, “ Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer,” Cancer Research, Vol. 66, No. 8, 2006, pp. 4049-4054. doi:10.1158/0008-5472.CAN-05-3813
 T. Mori, S. R. Martinez, S. J. O’Day, et al., “Estrogen Receptor-Alpha Methylation Predicts Melanoma Progression,” Cancer Research, Vol. 66, No. 13, 2006, pp. 6692-6698. doi:10.1158/0008-5472.CAN-06-0801
 T. Saito, M. Nishimura, H. Yamasaki and R. Kudo, “Hypermethylation in Promoter Region of E-cadherin Gene Is Associated with Tumor Differentiation and Myometrial Invasion in Endometrial Cancer,” Cancer, Vol. 97, No. 4, 2003, pp. 1002-1009. doi:10.1002/cncr.11157
 T. Z. Yi, J. Guo, L. Zhou, X. Chen, R. R. Mi, Q. X. Qu, J. H. Zheng and L. Zhai, “ Prognotic Value of E-cadherin Expression and CDH1 Promoter Hypermethylation in Patients with Endometrial Cancer,” Cancer Investigation, Vol. 29, No. 1, 2011, pp. 86-92. doi:10.3109/07357907.2010.512603
 M. Daskalakis, T. T. Nguyen, C. Nguyen, et al., “Demethylation of a Hypermethylated P15/INK4B Gene in Patients with Myelodysplastic Syndrome by 5-Aza-2’-Deoxycytidine [Decitabine] Treatment,” Blood, Vol. 100, No. 8, 2002, pp. 2957-2964. doi:10.1182/blood.V100.8.2957
 J. P. Issa, G. Garcia-Manero, F. J. Giles, et al., “Phase 1 Study of Low-Dose Prolonged Exposure Schedules of the Hypomethylating Agent 5-aza-2’-Deoxycytidine [Decitabine] in Hematopoietic Malignancies,” Blood, Vol. 103, No. 5, 2003, pp. 1635-1640. doi:10.1182/blood-2003-03-0687
 D. Kang, J. Chen, J. Wong and G. Fang, “The Checkpoint Protein CHFR Is a Ligase That Ubiquitinates Plk1 and Inhibits Cdc2 at the G2 to M Transition,” Journal of Cell Biology, Vol. 156, No. 2, 2002, pp. 249-259. doi:10.1083/jcb.200108016
 K. Ogi, M. Toyota, H. Mita, et al., “Small Interfering RNA-Induced CHFR Silencing Sensitizes Oral Squamous Cell Cancer Cells to Microtubule Inhibitors,” Cancer Biology & Therapy, Vol. 4, No. 7, 2005, pp. 773-780. doi:10.4161/cbt.4.7.1896
 K. Banno, M. Yanokura, M. Kawaguchi, et al., “Epigenetic Inactivation of the CHFR Gene in Cervical Cancer Contributes to Sensitivity to Taxanes,” International Journal of Oncology, Vol. 31, No. 4, 2007, pp. 713-720.
 Y. Koga, Y. Kitajima, A. Miyoshi, K. Sato, S. Sato and K. Miyazaki, “The Significance of Aberrant CHFR Methylation for Clinical Response to Microtubule Inhibitors in Gastric Cancer,” Journal of Gastroenterology, Vol. 41, No. 2, 2006, pp. 133-139. doi:10.1007/s00535-005-1732-7